Every financial statement,
one clean chart.
Search any US-listed company. Data straight from SEC filings.
IMMUNOVANT, INC. (IMVT), most recent 12 months reported: net loss $538.22M, free cash flow -$407.32M. Latest balance sheet on file: liquid cash $797.8M. From SEC filings. More on IMMUNOVANT, INC.: Profitability · Cash flow · Debt Others in Biological Products, (No Diagnostic Substances): EXOZYMES INC. · GREEN PLANET BIOENGINEERING CO., LTD. · GREENLAND MINES LTD · Inhibikase Therapeutics, Inc. · IN8BIO, INC. · MiNK Therapeutics, Inc. · INTENSITY THERAPEUTICS, INC. · Quince Therapeutics, Inc.
Filter every US company by the numbers — net cash, margins, ROIC, growth. Looking for one company? The search box above is free.
Follow a company and we'll email you when it files a quarterly or annual report with the SEC. Free follows 3 companies; Pro follows up to 500, and sorts and filters them.